Because of a price gap between manufacturing costs and drug prices, the development of IL-6 mAb for autoimmune diseases was initially abandoned, and the focus was diverted toward the development of drugs for multiple myeloma instead. This evidence concerns the gene IL6 and plasma cell myeloma.